<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD03720000_2</Organism_ID>
  <Organism>Rat</Organism>
  <Organism_Latin>Rattus norvegicus</Organism_Latin>
  <UniProt_ID>P13053</UniProt_ID>
  <Seq_Length>423</Seq_Length>
  <Molecule_Weight>47814</Molecule_Weight>
  <KEGG_ID>rno:24873</KEGG_ID>
  <Orthology_ID>K08539</Orthology_ID>
  <Function_Summary>Nuclear hormone receptor. Transcription factor that mediates the action of vitamin D3 by controlling the expression of hormone sensitive genes. Regulates transcription of hormone sensitive genes via its association with the WINAC complex, a chromatin-remodeling complex. Recruited to promoters via its interaction with the WINAC complex subunit BAZ1B/WSTF, which mediates the interaction with acetylated histones, an essential step for VDR-promoter association. Plays a central role in calcium homeostasis.</Function_Summary>
  <Pfam_ID>PF00104:Hormone_recep@@PF00105:zf-C4</Pfam_ID>
  <Allosteric_Activator_Count>10</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>4</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Nuclear receptor subfamily 1 group I member 1</Alias>
      <Alias>VDR</Alias>
      <Alias>1,25-dihydroxyvitamin D3 receptor</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Any molecular function by which a gene product interacts selectively with DNA (deoxyribonucleic acid).</Detail>
      <Keyword>DNA binding</Keyword>
      <Ontology_ID>GO:0003677</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any metal ion.</Detail>
      <Keyword>Metal ion binding</Keyword>
      <Ontology_ID>GO:0046872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with vitamin D3, cholecalciferol, to initiate a change in cell activity.</Detail>
      <Keyword>Vitamin D3 receptor activity</Keyword>
      <Ontology_ID>GO:0008434</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with vitamin D, any of a group of related, fat-soluble compounds that are derived from delta-5,7 steroids and play a central role in calcium metabolism. Specific forms of vitamin D include calciferol (ergocalciferol; vitamin D2) and cholecalciferol (calciol; vitamin D3).</Detail>
      <Keyword>Vitamin D binding</Keyword>
      <Ontology_ID>GO:0005499</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with DNA of a specific nucleotide composition, e.g. GC-rich DNA binding, or with a specific sequence motif or type of DNA e.g. promotor binding or rDNA binding.</Detail>
      <Keyword>Sequence-specific DNA binding</Keyword>
      <Ontology_ID>GO:0043565</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with a steroid hormone to initiate a change in cell activity.</Detail>
      <Keyword>Steroid hormone receptor activity</Keyword>
      <Ontology_ID>GO:0003707</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with an extracellular or intracellular messenger to initiate a change in cell activity.</Detail>
      <Keyword>Receptor activity</Keyword>
      <Ontology_ID>GO:0004872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with zinc (Zn) ions.</Detail>
      <Keyword>Zinc ion binding</Keyword>
      <Ontology_ID>GO:0008270</Ontology_ID>
    </Funtion>
  </Function_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>A change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a calcium ion stimulus.</Detail>
      <Keyword>Response to calcium ion</Keyword>
      <Ontology_ID>GO:0051592</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Regulation of transcription</Keyword>
      <Ontology_ID>GO:0045449</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The inherent decline over time, from the optimal fertility and viability of early maturity, that may precede death and may be preceded by other indications, such as sterility.</Detail>
      <Keyword>Aging</Keyword>
      <Ontology_ID>GO:0007568</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process induced by extracellular signals that directly activates any of the steps required for cell death by apoptosis.</Detail>
      <Keyword>Induction of apoptosis by extracellular signals</Keyword>
      <Ontology_ID>GO:0008624</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of stimulus by estradiol, a C18 steroid hormone hydroxylated at C3 and C17 that acts as a potent estrogen.</Detail>
      <Keyword>Response to estradiol stimulus</Keyword>
      <Ontology_ID>GO:0032355</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Transcription</Keyword>
      <Ontology_ID>GO:0006350</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the directed movement of calcium ions via the activity of voltage-gated calcium channels.</Detail>
      <Keyword>Positive regulation of calcium ion transport via voltage-gated calcium channel activity</Keyword>
      <Ontology_ID>GO:0051929</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <Molecule_Seq>
    <Protein_Seq>MEATAASTSLPDPGDFDRNVPRICGVCGDRATGFHFNAMTCEGCKGFFRRSMKRKALFTCPFNGDCRITKDNRRHCQACRLKRCVDIGMMKEFILTDEEVQRKREMIMKRKEEEALKDSLRPKLSEEQQHIIAILLDAHHKTYDPTYADFRDFRPPVRMDGSTGSYSPRPTLSFSGNSSSSSSDLYTTSLDMMEPSGFSNLDLNGEDSDDPSVTLDLSPLSMLPHLADLVSYSIQKVIGFAKMIPGFRDLTSDDQIVLLKSSAIEVIMLRSNQSFTMDDMSWDCGSQDYKYDVTDVSKAGHTLELIEPLIKFQVGLKKLNLHEEEHVLLMAICIVSPDRPGVQDAKLVEAIQDRLSNTLQTYIRCRHPPPGSHQLYAKMIQKLADLRSLNEEHSKQYRSLSFQPENSMKLTPLVLEVFGNEIS</Protein_Seq>
    <DNA_Seq>CGTCCACCGCCAGACCAGAGTTCTTTTGGTCGGACAGATCTGTGAGACTTCCAGGAGAGCACCCTTGGGCTCTACTCACCCTGCTCCTTCAGGGATGGAGGCAACAGCGGCCAGCACCTCCCTGCCCGACCCTGGTGACTTTGACCGGAACGTGCCCCGGATCTGTGGAGTGTGTGGAGACCGAGCCACAGGCTTCCACTTCAATGCTATGACCTGTGAAGGCTGCAAAGGTTTCTTCAGGCGGAGCATGAAGCGGAAGGCCCTGTTCACCTGTCCCTTCAATGGAGATTGCCGCATCACCAAGGACAACCGGCGACACTGCCAGGCCTGCCGGCTCAAACGCTGTGTGGACATCGGCATGATGAAGGAGTTCATCCTGACAGATGAGGAGGTACAGCGTAAGAGGGAGATGATAATGAAGAGAAAAGAGGAAGAGGCCTTGAAGGACAGTCTGAGGCCCAAGCTATCTGAAGAACAACAGCACATCATAGCCATCCTGCTGGACGCCCACCACAAGACCTATGACCCCACCTACGCTGACTTCAGGGACTTCCGGCCTCCAGTTCGTATGGACGGAAGTACAGGGAGCTATTCTCCAAGGCCCACACTCAGCTTCTCCGGGAACTCCTCCTCCTCCAGCTCTGACCTGTACACCACCTCACTAGACATGATGGAACCATCCGGCTTTTCCAACCTGGATCTGAACGGAGAGGATTCTGATGACCCGTCTGTGACTCTGGACCTGTCTCCTCTCTCCATGCTGCCCCACCTGGCTGACCTTGTCAGTTACAGCATCCAAAAGGTCATCGGCTTTGCCAAGATGATCCCAGGATTCAGGGATCTCACCTCCGATGACCAGATTGTCCTGCTTAAGTCAAGCGCCATTGAGGTGATCATGTTACGCTCCAACCAGTCTTTCACCATGGATGATATGTCCTGGGACTGTGGCAGCCAGGACTACAAGTACGACGTCACCGATGTCTCCAAAGCTGGGCACACCCTGGAGCTGATCGAGCCCCTCATAAAGTTCCAGGTGGGGCTGAAGAAGCTGAACTTACATGAGGAAGAGCATGTCCTTCTCATGGCCATCTGCATTGTCTCCCCGGACCGACCTGGGGTCCAGGACGCCAAGCTGGTGGAAGCCATTCAGGACCGCCTATCCAACACGCTGCAGACCTACATCCGCTGCCGCCACCCGCCCCCAGGCAGCCACCAGCTCTATGCCAAGATGATCCAGAAACTGGCCGACCTGCGGAGCCTCAACGAGGAACACTCCAAACAATACCGCTCCCTCTCCTTCCAGCCCGAGAATAGCATGAAGCTCACACCCCTTGTGCTGGAGGTGTTCGGCAATGAGATCTCCTGACCAGGGTGGCCCACAGTGGTGCCTGGGTAGGGCCGCTCCTCCAGAGCCCTGTGCCCAGGCCCTGGGCTTGGTTGCAGCCCAGCAGTGCCTCCTGCCCTTTCTGGAGTTCAGTCCTTCCTCTGCCATGGCCTCTGTCTGTCTGCCTCATCCTTTCTCCTGCCCAGCCTAACACCTGGTCTCCCTTTCCTGTAGACCTCGAGTTGCTCCTGTCTCTTGAGACCTCAGTTAGGAGAGGCTGCTGTTTATCTGACAAAGGAACTCAATTGGGGATAGAGGGCAGGGGCTGAAGGCGGAACTCTGCCTAGGGGATGCCTCCACCACAAGGGGCTGCTGCTTGTGTCAAGGGAGGCAGGCAGAAGAGACGCATTCACTCCTCAGGGACAGGTACCTGCACCTCCCCTCACTCCAGCCCTACCTGCCCAAAGCCTAGTGAGAAATCTGGCCCCTGCCTGCGAAGGGTACACAACCTACCCATCATCCCTACTGTGTCCCGTCTCGTCCTGCCGCCTGTCTGTGTTATTCTGACCCGGGGGAGTAGGTCACTGAGGGGCCTCCTTCCTCTGCCTTTATACTCACGGGGCTCACTCACTGCCAAGATGACCAAATACACTACCACACGAACCAAGGAGCACTCACCCAGCCCTGCAGTTCCCACCTTTGAGGTTTTGCCATGGGAA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Bone</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Intestine</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Kidney</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>Vdr</Gene_Name>
    <Gene_Alias>Nr1i1</Gene_Alias>
    <Gene_ID>24873</Gene_ID>
    <Genbank_ACCN>NM_017058</Genbank_ACCN>
    <Protein_ACCN>NP_058754</Protein_ACCN>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/24873</Gene_URL>
    <UCSC_ID>NM_017058</UCSC_ID>
  </Gene>
  <PDB_List>
    <PDB>
      <PDB_Title>2-Substituted-16-ene-22-thia-1alpha,25-dihydroxy-26,27-dimethyl-19-norvitamin D3 analogs: Synthesis, biological evaluation and crystal structure</PDB_Title>
      <PDB_ID>2ZLC</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZLC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>5-{2-[1-(5-HYDROXY-1,5-DIMETHYL-HEXYL)-7A- METHYL-OCTAHYDRO-INDEN-4-YLIDENE]
-ETHYLIDENE}- 4-METHYLENE-CYCLOHEXANE-1,3-DIOL</Ligand_Name>
      <PubMed_Title>2-Substituted-16-ene-22-thia-1alpha,25-dihydroxy-26,27-dimethyl-19-norvitamin D3 analogs: Synthesis, biological evaluation, and crystal structure</PubMed_Title>
      <Author>Shimizu M, et al.</Author>
      <Journal>Bioorg Med Chem.2008 Jul 15;16(14):6949-64. Epub  2008 May 27.</Journal>
      <PubMed_ID>18539034</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>2-Substituted-16-ene-22-thia-1alpha,25-dihydroxy-26,27-dimethyl-19-norvitamin D3 analogs: Synthesis, biological evaluation and crystal structure</PDB_Title>
      <PDB_ID>2ZL9</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZL9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>(1R,2R,3R,5Z)-17-{(1S)-1-[(2-ethyl-2-hydroxybutyl)sulfanyl]ethyl}- 2-(2
-hydroxyethoxy)-9,10-secoestra-5,7,16- triene-1,3-diol</Ligand_Name>
      <PubMed_Title>2-Substituted-16-ene-22-thia-1alpha,25-dihydroxy-26,27-dimethyl-19-norvitamin D3 analogs: Synthesis, biological evaluation, and crystal structure</PubMed_Title>
      <Author>Shimizu M, et al.</Author>
      <Journal>Bioorg Med Chem.2008 Jul 15;16(14):6949-64. Epub  2008 May 27.</Journal>
      <PubMed_ID>18539034</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>2-Substituted-16-ene-22-thia-1alpha,25-dihydroxy-26,27-dimethyl-19-norvitamin D3 analogs: Synthesis, biological evaluation and crystal structure</PDB_Title>
      <PDB_ID>2ZLA</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZLA</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>(1R,2S,3R,5Z,7E)-17-{(1R)-1-[(2-ethyl-2-hydroxybutyl)sulfanyl]ethyl}- 2-(2
-hydroxyethoxy)-9,10-secoestra-5,7,16- triene-1,3-diol</Ligand_Name>
      <PubMed_Title>2-Substituted-16-ene-22-thia-1alpha,25-dihydroxy-26,27-dimethyl-19-norvitamin D3 analogs: Synthesis, biological evaluation, and crystal structure</PubMed_Title>
      <Author>Shimizu M, et al.</Author>
      <Journal>Bioorg Med Chem.2008 Jul 15;16(14):6949-64. Epub  2008 May 27.</Journal>
      <PubMed_ID>18539034</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Rat Vitamin D Receptor Ligand Binding Domain Complexed with VitIII 17-20Z and the NR2 Box of DRIP 205</PDB_Title>
      <PDB_ID>2O4J</PDB_ID>
      <Resolution>1.74</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2O4J</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>(1R,3R,7E,17Z)-17-(5-hydroxy-1,5-dimethylhexylidene)- 2-methylene-9,10-secoestra
-5,7-diene-1,3- diol</Ligand_Name>
      <PubMed_Title>New analogs of 2-methylene-19-nor-(20S)-1,25-dihydroxyvitamin D(3) with conformationally restricted side chains: Evaluation of biological activity and structural determination of VDR-bound conformations.</PubMed_Title>
      <Author>Vanhooke JL, et al.</Author>
      <Journal>Arch Biochem Biophys.2007 Apr 15;460(2):161-5. Epub  2006 Dec 12.</Journal>
      <PubMed_ID>17227670</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Rat Vitamin D Receptor Ligand Binding Domain Complexed with VitIII 17-20E and the NR2 Box of DRIP 205</PDB_Title>
      <PDB_ID>2O4R</PDB_ID>
      <Resolution>1.98</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2O4R</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>(1R,3R,7E,17E)-17-(5-hydroxy-1,5-dimethylhexylidene)- 2-methylene-9,10-secoestra
-5,7-diene-1,3- diol</Ligand_Name>
      <PubMed_Title>New analogs of 2-methylene-19-nor-(20S)-1,25-dihydroxyvitamin D(3) with conformationally restricted side chains: Evaluation of biological activity and structural determination of VDR-bound conformations.</PubMed_Title>
      <Author>Vanhooke JL, et al.</Author>
      <Journal>Arch Biochem Biophys.2007 Apr 15;460(2):161-5. Epub  2006 Dec 12.</Journal>
      <PubMed_ID>17227670</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>A New Class of Vitamin D Receptor Ligands that Induce Structural Rearrangement of the Ligand-binding Pocket</PDB_Title>
      <PDB_ID>2ZXM</PDB_ID>
      <Resolution>3.01</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZXM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R,3S)- 3-(2-hydroxyethyl)heptan-2-yl]-7a
-methyl- 2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]- 4-methylidene
-cyclohexane-1,3-diol</Ligand_Name>
      <PubMed_Title>A New Class of Vitamin D Analogues that Induce Structural Rearrangement of the Ligand-Binding Pocket of the Receptor</PubMed_Title>
      <Author>Inaba Y, et al.</Author>
      <Journal>J Med Chem.2009 Feb 4. [Epub ahead of print]</Journal>
      <PubMed_ID>19193059</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>crystal structure of the rat vitamin D receptor ligand binding domain complexed with 1,25-dihydroxyvitamin D3 and a synthetic peptide containing the NR2 box of DRIP 205</PDB_Title>
      <PDB_ID>1RK3</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1RK3</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03720001</ASD_Ligand>
      <Ligand_Name>5-{2-[1-(5-HYDROXY-1,5-DIMETHYL-HEXYL)-7A- METHYL-OCTAHYDRO-INDEN-4-YLIDENE]
-ETHYLIDENE}- 4-METHYLENE-CYCLOHEXANE-1,3-DIOL</Ligand_Name>
      <PubMed_Title>Molecular Structure of the Rat Vitamin D Receptor Ligand Binding Domain Complexed with 2-Carbon-Substituted Vitamin D(3) Hormone Analogues and a LXXLL-Containing Coactivator Peptide</PubMed_Title>
      <Author>Vanhooke JL, et al.</Author>
      <Journal>Biochemistry.2004 Apr 13;43(14):4101-10.</Journal>
      <PubMed_ID>15065852</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>crystal structure of the rat vitamin D receptor ligand binding domain complexed with 2MbisP and a synthetic peptide containing the NR2 box of DRIP 205</PDB_Title>
      <PDB_ID>1RKG</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1RKG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>5-{2-[1-(1-METHYL-PROPYL)-7A-METHYL-OCTAHYDRO- INDEN-4-YLIDENE]-ETHYLIDENE}-2
-METHYLENE- CYCLOHEXANE-1,3-DIOL</Ligand_Name>
      <PubMed_Title>Molecular Structure of the Rat Vitamin D Receptor Ligand Binding Domain Complexed with 2-Carbon-Substituted Vitamin D(3) Hormone Analogues and a LXXLL-Containing Coactivator Peptide</PubMed_Title>
      <Author>Vanhooke JL, et al.</Author>
      <Journal>Biochemistry.2004 Apr 13;43(14):4101-10.</Journal>
      <PubMed_ID>15065852</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Rat Vitamin D Receptor Bound to Adamantyl Vitamin D Analogs: Structural Basis for Vitamin D Receptor Antagonism and/or Partial Agonism</PDB_Title>
      <PDB_ID>2ZMH</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZMH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>(1R,3R,7E,17beta)-17-{(1R,2E,4R)-4-hydroxy- 1-methyl-4-[(3S,5S,7S)-tricyclo
[3.3.1.1~3,7~]dec- 1-yl]but-2-en-1-yl}-2-methylidene-9,10-secoestra- 5,7-diene-1,3
-diol</Ligand_Name>
      <PubMed_Title>Crystal structures of rat vitamin d receptor bound to adamantyl vitamin d analogs: structural basis for vitamin d receptor antagonism and partial agonism</PubMed_Title>
      <Author>Nakabayashi M, et al.</Author>
      <Journal>J Med Chem.2008 Sep 11;51(17):5320-9. Epub  2008 Aug 19.</Journal>
      <PubMed_ID>18710208</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>crystal structure of the rat vitamin D receptor ligand binding domain complexed with 2MD and a synthetic peptide containing the NR2 box of DRIP 205</PDB_Title>
      <PDB_ID>1RJK</PDB_ID>
      <Resolution>1.99</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1RJK</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03720001</ASD_Ligand>
      <Ligand_Name>5-{2-[1-(5-HYDROXY-1,5-DIMETHYL-HEXYL)-7A- METHYL-OCTAHYDRO-INDEN-4-YLIDENE]
-ETHYLIDENE}- 2-METHYLENE-CYCLOHEXANE-1,3-DIOL</Ligand_Name>
      <PubMed_Title>Molecular Structure of the Rat Vitamin D Receptor Ligand Binding Domain Complexed with 2-Carbon-Substituted Vitamin D(3) Hormone Analogues and a LXXLL-Containing Coactivator Peptide</PubMed_Title>
      <Author>Vanhooke JL, et al.</Author>
      <Journal>Biochemistry.2004 Apr 13;43(14):4101-10.</Journal>
      <PubMed_ID>15065852</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>A New Class of Vitamin D Receptor Ligands that Induce Structural Rearrangement of the Ligand-binding Pocket</PDB_Title>
      <PDB_ID>2ZXN</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZXN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2S,3S)- 3-(2-hydroxyethyl)heptan-2-yl]-7a
-methyl- 2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]- 4-methylidene
-cyclohexane-1,3-diol</Ligand_Name>
      <PubMed_Title>A New Class of Vitamin D Analogues that Induce Structural Rearrangement of the Ligand-Binding Pocket of the Receptor</PubMed_Title>
      <Author>Inaba Y, et al.</Author>
      <Journal>J Med Chem.2009 Feb 4. [Epub ahead of print]</Journal>
      <PubMed_ID>19193059</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the rat vitamin D receptor ligand binding domain complexed with YR301 and a synthetic peptide containing the NR2 box of DRIP 205</PDB_Title>
      <PDB_ID>2ZFX</PDB_ID>
      <Resolution>1.99</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZFX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>(2S)-3-{4-[1-ethyl-1-(4-{[(2R)-2-hydroxy- 3,3-dimethylbutyl]oxy}-3
-methylphenyl)propyl]- 2-methylphenoxy}propane-1,2-diol</Ligand_Name>
      <PubMed_Title>Structure of the ligand-binding domain of rat VDR in complex with the nonsecosteroidal vitamin D3 analogue YR301</PubMed_Title>
      <Author>Kakuda S, et al.</Author>
      <Journal>Acta Crystallogr Sect F Struct Biol Cryst Commun.2008 Nov 1;64(Pt 11):970-3. Epub  2008 Oct 31.</Journal>
      <PubMed_ID>18997319</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>crystal structure of the rat vitamin D receptor ligand binding domain complexed with 2AM20R and a synthetic peptide containing the NR2 box of DRIP 205</PDB_Title>
      <PDB_ID>1RKH</PDB_ID>
      <Resolution>2.28</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1RKH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>5-{2-[1-(5-HYDROXY-1,5-DIMETHYL-HEXYL)-7A- METHYL-OCTAHYDRO-INDEN-4-YLIDENE]
-ETHYLIDENE}- 2-METHYL-CYCLOHEXANE-1,3-DIOL</Ligand_Name>
      <PubMed_Title>Molecular Structure of the Rat Vitamin D Receptor Ligand Binding Domain Complexed with 2-Carbon-Substituted Vitamin D(3) Hormone Analogues and a LXXLL-Containing Coactivator Peptide</PubMed_Title>
      <Author>Vanhooke JL, et al.</Author>
      <Journal>Biochemistry.2004 Apr 13;43(14):4101-10.</Journal>
      <PubMed_ID>15065852</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Rat Vitamin D Receptor Bound to Adamantyl Vitamin D Analogs: Structural Basis for Vitamin D Receptor Antagonism and/or Partial Agonism</PDB_Title>
      <PDB_ID>2ZMJ</PDB_ID>
      <Resolution>2.35</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZMJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>(1R,3R,7E,17beta)-17-{(1S,2E,5R)-5-hydroxy- 1-methyl-6-[(3S,5S,7S)-tricyclo
[3.3.1.1~3,7~]dec- 1-yl]hex-2-en-1-yl}-2-methylidene-9,10-secoestra- 5,7-diene-1,3
-diol</Ligand_Name>
      <PubMed_Title>Crystal structures of rat vitamin d receptor bound to adamantyl vitamin d analogs: structural basis for vitamin d receptor antagonism and partial agonism</PubMed_Title>
      <Author>Nakabayashi M, et al.</Author>
      <Journal>J Med Chem.2008 Sep 11;51(17):5320-9. Epub  2008 Aug 19.</Journal>
      <PubMed_ID>18710208</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Rat Vitamin D Receptor Bound to Adamantyl Vitamin D Analogs: Structural Basis for Vitamin D Receptor Antagonism and/or Partial Agonism</PDB_Title>
      <PDB_ID>2ZMI</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZMI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>1,2-ETHANEDIOL$FORMIC ACID$(1R,3R,7E,17beta)-17-{(1S,2E,5R)-5-hydroxy- 1-methyl-5-[(3S,5S,7S)-tricyclo
[3.3.1.1~3,7~]dec- 1-yl]pent-2-en-1-yl}-2-methylidene-9,10-secoestra- 5,7-diene-1,3
-diol</Ligand_Name>
      <PubMed_Title>Crystal structures of rat vitamin d receptor bound to adamantyl vitamin d analogs: structural basis for vitamin d receptor antagonism and partial agonism</PubMed_Title>
      <Author>Nakabayashi M, et al.</Author>
      <Journal>J Med Chem.2008 Sep 11;51(17):5320-9. Epub  2008 Aug 19.</Journal>
      <PubMed_ID>18710208</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko05152</Pathway_ID>
      <Pathway_Title>Tuberculosis</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04978</Pathway_ID>
      <Pathway_Title>Mineral absorption</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Digestive system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04961</Pathway_ID>
      <Pathway_Title>Endocrine and other factor-regulated calcium reabsorption</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Excretory system</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>All alpha proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.b.cdh.b.b.cb.html</SCOP_URL>
    <CATH_Class>Mainly alpha</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1rjk</CATH_URL>
  </Fold>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD03720001</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03720002</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03720003</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03720004</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03720005</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03720006</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03720007</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03720008</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03720009</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03720010</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03720011</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03720012</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03720013</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03720014</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-05-31</Create_Date>
</Organism_Record>